Webb12 apr. 2024 · Aerami Therapeutics will take its lead, inhaled asset AER-901 into Phase II testing for two serious and rare forms of pulmonary hypertension later this year. Company leaders believe their formulation of imatinib will provide improved treatment efficacy for patients. The Durham-based company will aim the drug-device combination at both … WebbTreprostinil is a stable analogue of prostacyclin, which promotes direct vasodilation of pulmonary and systemic arterial vascular beds and inhibits platelet aggregation. The phase 3, multicenter, randomized, double-blind, placebo-controlled, 16–week, parallel-group INCREASE study evaluated inhaled treprostinil in patients with PH-ILD.
Inhaled siRNA nanoparticles targeting - Science Advances
Webb23 mars 2024 · An inhalable platform for mRNA therapeutics would enable minimally invasive and lung targeted delivery for a host of pulmonary diseases. Development of lung targeted mRNA therapeutics has been limited by poor transfection efficiency and risk of vehicle-induced pathology. Here we report an inhalable polymer-based vehicle for … Webb12 apr. 2024 · The role of inhaled antifungals for prophylaxis and treatment of invasive fungal pneumonias remains undefined. Herein we summarize recent clinically relevant literature in high-risk groups such as neutropenic hematology patients, including those undergoing stem cell transplant, lung and other solid transplant recipients, and those … fivem background 4k
Eric Shen, PharmD - Associate Director, Global Medical ... - LinkedIn
Webbför 7 timmar sedan · UCD spin-out Aer Therapeutics has raised $36 million (€32.5 million) to develop a drug for patients with chronic obstructive pulmonary disease (COPD). The … WebbTYVASO treats at the site of disease1,2. TYVASO is inhaled directly to distal airspaces that are in close proximity to pulmonary arterioles affected by pulmonary hypertension.3. Direct-to-lung delivery results in higher concentrations in the pulmonary arterial vasculature, which may selectively enhance blood flow for better ventilation and ... Webb25 aug. 2024 · DURHAM, N.C., Aug. 25, 2024 (GLOBE NEWSWIRE) -- Aerami Therapeutics, Inc. a clinical stage biopharmaceutical company developing inhaled therapies to treat severe respiratory and chronic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted the company orphan drug designation … can i stash money in my checked luggage